CXCL9 and neoplasm: Furthermore, in keeping with the effect of EZH2 inhibition in tumor cells (Figure 3B), Mo-TAMs from EPZ-6438-treated MCS showed a consistent enhanced expression of monocyte chemoattractants CCL2 and VEGF but not Th1-recruiting chemokines (CXCL9, CXCL10, CXCL11).